Our top pick for
Tenax Therapeutics, Inc is a biotechnology business based in the US. Tenax Therapeutics shares (TENX) are listed on the NASDAQ and all prices are listed in US Dollars. Tenax Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of USD$13.5 million.
|Latest market close||USD$1.09|
|52-week range||USD$0.45 - USD$2.68|
|50-day moving average||USD$1.059|
|200-day moving average||USD$1.2383|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.945|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||N/A|
|1 month (2020-12-15)||N/A|
|3 months (2020-10-15)||N/A|
|6 months (2020-07-15)||N/A|
|1 year (2020-01-15)||N/A|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-73.4%|
|Return on equity TTM||-140.79%|
|Market capitalisation||USD$13.5 million|
TTM: trailing 12 months
There are currently 26,721 Tenax Therapeutics shares held short by investors – that's known as Tenax Therapeutics's "short interest". This figure is 65.3% down from 76,997 last month.
There are a few different ways that this level of interest in shorting Tenax Therapeutics shares can be evaluated.
Tenax Therapeutics's "short interest ratio" (SIR) is the quantity of Tenax Therapeutics shares currently shorted divided by the average quantity of Tenax Therapeutics shares traded daily (recently around 133605). Tenax Therapeutics's SIR currently stands at 0.2. In other words for every 100,000 Tenax Therapeutics shares traded daily on the market, roughly 200 shares are currently held short.
However Tenax Therapeutics's short interest can also be evaluated against the total number of Tenax Therapeutics shares, or, against the total number of tradable Tenax Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tenax Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Tenax Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Tenax Therapeutics shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tenax Therapeutics.
Find out more about how you can short Tenax Therapeutics stock.
We're not expecting Tenax Therapeutics to pay a dividend over the next 12 months.
Tenax Therapeutics's shares were split on a 1:20 basis on 26 February 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tenax Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Tenax Therapeutics shares which in turn could have impacted Tenax Therapeutics's share price.
Over the last 12 months, Tenax Therapeutics's shares have ranged in value from as little as $0.45 up to $2.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tenax Therapeutics's is 2.2845. This would suggest that Tenax Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.